TY - JOUR
T1 - Leptin Reduction as a Required Component for Weight Loss
AU - Zhao, Shangang
AU - Li, Na
AU - Xiong, Wei
AU - Li, Guannan
AU - He, Sijia
AU - Zhang, Zhuzhen
AU - Zhu, Qingzhang
AU - Jiang, Nisi
AU - Ikejiofor, Christian
AU - Zhu, Yi
AU - Wang, May-Yun
AU - Han, Xianlin
AU - Zhang, Ningyang
AU - Solis-Herrera, Carolina
AU - Kusminski, Christine
AU - An, Zhiqiang
AU - Elmquist, Joel K
AU - Scherer, Philipp E
N1 - © 2024 by the American Diabetes Association.
PY - 2024/2/1
Y1 - 2024/2/1
N2 - Partial leptin reduction can induce significant weight loss, while weight loss contributes to partial leptin reduction. The cause-and-effect relationship between leptin reduction and weight loss remains to be further elucidated. Here, we show that FGF21 and the glucagon-like peptide 1 receptor (GLP-1R) agonist liraglutide rapidly induced a reduction in leptin. This leptin reduction contributed to the beneficial effects of GLP-1R agonism in metabolic health, as transgenically maintaining leptin levels during treatment partially curtailed the beneficial effects seen with these agonists. Moreover, a higher degree of leptin reduction during treatment, induced by including a leptin neutralizing antibody with either FGF21 or liraglutide, synergistically induced greater weight loss and better glucose tolerance in diet-induced obese mice. Furthermore, upon cessation of either liraglutide or FGF21 treatment, the expected immediate weight regain was observed, associated with a rapid increase in circulating leptin levels. Prevention of this leptin surge with leptin neutralizing antibodies slowed down weight gain and preserved better glucose tolerance. Mechanistically, a significant reduction in leptin induced a higher degree of leptin sensitivity in hypothalamic neurons. Our observations support a model that postulates that a reduction of leptin levels is a necessary prerequisite for substantial weight loss, and partial leptin reduction is a viable strategy to treat obesity and its associated insulin resistance.
AB - Partial leptin reduction can induce significant weight loss, while weight loss contributes to partial leptin reduction. The cause-and-effect relationship between leptin reduction and weight loss remains to be further elucidated. Here, we show that FGF21 and the glucagon-like peptide 1 receptor (GLP-1R) agonist liraglutide rapidly induced a reduction in leptin. This leptin reduction contributed to the beneficial effects of GLP-1R agonism in metabolic health, as transgenically maintaining leptin levels during treatment partially curtailed the beneficial effects seen with these agonists. Moreover, a higher degree of leptin reduction during treatment, induced by including a leptin neutralizing antibody with either FGF21 or liraglutide, synergistically induced greater weight loss and better glucose tolerance in diet-induced obese mice. Furthermore, upon cessation of either liraglutide or FGF21 treatment, the expected immediate weight regain was observed, associated with a rapid increase in circulating leptin levels. Prevention of this leptin surge with leptin neutralizing antibodies slowed down weight gain and preserved better glucose tolerance. Mechanistically, a significant reduction in leptin induced a higher degree of leptin sensitivity in hypothalamic neurons. Our observations support a model that postulates that a reduction of leptin levels is a necessary prerequisite for substantial weight loss, and partial leptin reduction is a viable strategy to treat obesity and its associated insulin resistance.
KW - Animals
KW - Mice
KW - Leptin/metabolism
KW - Liraglutide/pharmacology
KW - Obesity
KW - Weight Loss
KW - Glucose/metabolism
KW - Glucagon-Like Peptide-1 Receptor/metabolism
U2 - 10.2337/db23-0571
DO - 10.2337/db23-0571
M3 - Article
C2 - 37935033
SN - 0012-1797
VL - 73
SP - 197
EP - 210
JO - Diabetes
JF - Diabetes
IS - 2
ER -